SCIG administration: A promising and patient convenient alternative for those receiving long-term IVIG

Background: Intravenous immunoglobulin (IVIG) therapy has been used as antibody replacement therapy in primary immunodeficiency diseases (PID) for more than 50 years. In this study, we aimed to define IVIG usage and adverse reactions and complications in PID and explain how subcutaneous immunoglobul...

Descripción completa

Detalles Bibliográficos
Autores principales: Hassini, Slim, Samuel, Soosan, Shibul, Sibi, Al-Nesf, Maryam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: HBKU Press 2022
Materias:
First Qatar Allergy Conference
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284658/
https://www.ncbi.nlm.nih.gov/pubmed/35909401
http://dx.doi.org/10.5339/qmj.2022.fqac.29

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284658/
https://www.ncbi.nlm.nih.gov/pubmed/35909401
http://dx.doi.org/10.5339/qmj.2022.fqac.29

Ejemplares similares